Trial reportEuropean journal of nuclear medicine and molecular imaging2025
[
Trial report in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05006326 (A Prospective Study of Clinical Application of 68Ga-PSMA PET/MR for Diagnosis and Staging in Hepatocellular Carcinoma), which is not on this map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective Study of Clinical Application of 68Ga-PSMA PET/MR for Diagnosis and Staging in Hepatocellular Carcinoma
Who cites it
3 citing papers in PubMed.
- Diagnostic Performance of PSMA PET/MRI in Characterizing LI-RADS 3 Observations in Patients with Cirrhosis.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Enhanced NIR-II Nanoparticle Probe for PSMA-Targeted Molecular Imaging and Prostate Cancer Diagnosis.International journal of nanomedicine · 2025Article
- Non-invasive diagnosis of liver fibrosis via MRI using targeted gadolinium-based nanoparticles.European journal of nuclear medicine and molecular imaging · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeRadiolabeled probes targeting prostate-specific membrane antigen (PSMA) have been used in prostate cancer. Moreover, PSMA is also overexpressed on neovessels in hepatocellular carcinoma (HCC). This study aimed to preliminarily evaluate the diagnostic effectiveness of [
methodsPatients suspected of HCC were prospectively enrolled in this single-center study (NCT05006326, 2021-08-16) to perform [
resultsA total of 12 patients (ten men and two women; mean age 58.75 ± 12.08 years) were included. Ten patients were diagnosed with HCC, 2 with intrahepatic cholangiocarcinoma (ICC), and 4 with hemangioma. The SUVmax, TLR, TBR, and TPR of HCC primary tumors were higher than those of ICC and hemangioma. The diagnostic accuracy of [
conclusionUtilizing a hybrid PET/MRI system to combine [
trial registrationNCT05006326. Registered August 16, 2021, https://clinicaltrials.gov/study/NCT05006326 .
Indexed as
Identifiers
39570398What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.